Press releases
Feb 19 / 2019
Teva Finalizes Settlement with Federal Trade Commission to Resolve All Outstanding Litigation between the Parties
Feb 15 / 2019
Statement: AJOVY® (fremanezumab-vfrm) injection Access Update


Feb 13 / 2019
Teva Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 6 / 2019
Teva Announces U.S. Launch of a Generic Version of Sabril® (Vigabatrin)
The first generic version of Sabril® (vigabatrin) tablets to enter the US market.
Top Stories
Read the latest Teva news
A Day to Reflect and Drive Action
World Cancer Day
Uncovering Insights on Multiple Chronic Conditions
Narrative review represents a key milestone in Teva’s efforts to address multiple chronic conditions
Teva deploys new 2D barcode in fight against counterfeit drug market
The counterfeit drugs trade is thought to be the world’s largest fraud market, with billions of dollars making its way into the hands of organized crime gangs each year
Teva USA Named a Best Employer for Healthy Lifestyles
Our health and wellness benefits are officially award-winning — improving health not only for patients, but also for our employees and their families

Media Resources

Intended for use by media professionals; may be downloaded for non-commercial use 

Media Inquiries

Contact Teva Corporate Communications

Learn more

Media Kit

Files and resources for media use only

Download Teva Media Kit

Financial Reports

View Teva financial news on our global website

Learn more

Connect with us

Teva Social Media Guidelines

Learn more